About Us

Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of small-molecule medicines that directly bind and modify the biological function of RNA to treat disease. This new class of medicines, RNA-targeted small molecules (rSMs), can unlock the therapeutic potential of deeply researched, valuable targets that are not accessible with today’s drug discovery approaches. Moreover, rSMs open the vast and largely unexplored transcriptome to drug discovery efforts.

Arrakis’s proprietary platform enables the identification of tractable structural elements within an RNA, the assessment of the biological impact of binding to those elements, and the design of drug candidates. Our discovery platform integrates leading-edge RNA bioinformatic and structural tools, RNA-specific chemical and biological assays, and traditional medicinal chemistry to produce a pipeline of rSMs to treat a range of disease including neurology, oncology and rare genetic diseases.

Arrakis has brought together scientific leaders in RNA structure, chemistry, and biology to work alongside a highly experienced management team with a track record of building transformative biopharmaceutical companies and developing novel therapeutics.

The company is located in Waltham, MA and is backed by investors with unsurpassed experience in building pioneering biopharmaceutical companies.

Back to Top